Findings Presented at 2015 ASCO Annual Meeting Add to Breadth of KEYTRUDA® (pembrolizumab) Data; Anti-Tumor Activity Now Demonstrated in 13 Different Tumor Types
Dateline City:
KENILWORTH, N.J.
New Data Presented at ASCO in Multiple, Difficult-to-Treat Cancers, including Small Cell Lung, Esophageal and Ovarian Cancers
Registrational Studies for KEYTRUDA Ongoing in Eight Different Tumor Types
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced the first-time presentation of findings investigating
the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1
therapy, in multiple, difficult-to-treat cancers, including advanced
small cell lung cancer (SCLC), esophageal cancer and ovarian cancer from
the KEYNOTE-028 Phase 1b study.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-664-0282orClaire Mulhearn, 908-200-1889orInvestors:Joseph Romanelli, 908-740-1986orJustin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news
More News: Cancer | Cancer & Oncology | Esophagus Cancer | Lung Cancer | Merck | Ovarian Cancer | Ovaries | Pharmaceuticals | Small Cell Lung Cancer | Study